Center for Prostate Disease Research (CPDR)

Gregory Chesnut

quantitative proteomics. ddPCR. Large serum/whole mount biobank and now diverse organoid modeling

TBD

ddPCR based urine exosomal RNA assays, NanoString, FISH and IHC combinations (tissues)

TBD

Affiliated at USUHS

N/A

USCAP

Yes

Delighted to serve wider within network

EVMS/UT/UCLA

Paul Boutros

Proteomics, computational biology

Depends on the type of proteomics assay

Broad genomics core

Computational biology, only limited by compute activities

Effectively any modern-sequencer

N/A

CAP-CLIA

No

N/A

Fred Hutch Cancer Center

Cecilia Yeung

Molecular diagnostics - Next generation sequencing, digital PCR, methylation PCR, and other permutations of PCR, Long read sequencing, Hi-C sequencing, methylation sequencing. Pathology/immunohistochemistry - histology, tissue microarray, immunohistochemistry, multiplex immunohistochemistry, spatial proteomics (high plex immunohistochemistry), spatial transcriptomics, digital pathology

10,000

flow cytometry, antibody development, function screening, Elisa, western blot, Mass spec

20,000

Ion Torrent, illumina

0.05

CAP, lab to lab exchange

Yes

Our lab also has the capability to develop standards and controls. Happy to collaborate with other centers.

Johns Hopkins

Daniel Chan

Immunoassay and Clinical Chemistry platforms, mass spectrometry.

Several thousands.

Genomics - PCR, NGS, anatomic pathology

500

Three NovaSeq 6000 and two NovaSeq X.

analytic LOD of ~0.001%.

CAP and others

No

N/A

LungLife AI

Paul Pagano

Rare cell isolation and analysis (multi-parameter flow cytometry and fluorescent microscopy, nucleic acid analysis)

5000

ELISA, PCR, FISH

5000

N/A

N/A

CAP

No

N/A

LynxDx, Inc.

John Kitchen

OpenArray qPCR

15,000

N/A

N/A

N/A

N/A

N/A

N/A

In startup mode, currently resources devoted to clinical testing and internal development, fee for service limited to clinical samples.

Meso Scale Diagnostics, LLC. (MSD)

Martin Stengelin

MULTI-ARRAY multiplexed Immunoassays

>100,000

"Immunoassay development, Multiplexed assay panel development, N-PLEX (DNA/RNA multiplexed assays), Extracellular vesicle assays

>10,000

N/A

N/A

N/A

N/A

N/A

NIST

Hua-Jun He

Reference materials and assay methods development

2 to 3 reference materials development and assay validation

Quantitative PCR, digital PCR, NGS, flow cytometry and other instrumental analysis tools.

It dependents the time and efforts needed.

PGM, miSeq, iSeq, and Oxford Nanopore GridION

N/A

Metrology

N/A

We are a federal government laboratory, and we are not a CLIA-certified clinical laboratory. Happy to share our current RMs or research grade test materials developed under EDRN (free of charge). Develop customized RMs. Validate assays through orthogonal methods or interlab testing.

NCI

Wendy Wang

Grant management

Reference Samples

N/A

N/A

N/A

N/A

N/A

N/A

Program may be able to join BRL activities.

NYU

Leopoldo Segal

Sequencing for DNA/RNA, LC-MS Metabolomics, Nanostring. These are available though institutional cores though Nanostring is done in Dr. Pass lab (MPI of our BRL).

RNA and DNA sequencing: ~1,000. LC-MS: a few hundred each year. Otherwise: TBD

Luminex, scRNA seq, CyTOF, DSP GeoMx and COSmx, Visium, spatial metabolomics. These are available though institutional cores.

scRNA seq: on maybe ~100. luminex, CyTOF, DSP, Visium, spatial metabolomics: few hundreds

Illumina

N/A

N/A

N/A

N/A

Pacific Northwest National Laboratory

Tao Liu

Mass spectrometry-based proteomics, including both targeted and unbiased protein analysis, as well as spatial and single-cell proteomics capabilities.

targeted LC-MS: 1000.

PRISM-SRM (fractionation coupled to LC-MS):300. untargeted proteomics: 400.

Mass spectrometry-based metabolomics.

600 samples for metabolomics.

N/A

N/A

N/A

N/A

As an IAA, we do not have a BDL component; however, we can work with any BDL or BRL for both biomarker discovery and/or validation studies.

University of California, Los Angeles (BU-UCLA)

Michael Palazzolo

Veracyte: nasal epithelium RNA whole transcriptome sequencing; LungLife AI: blood-based custom 4-color FISH assay test; Imaging BRL: image archiving, quality control, segmentation/annotation

TBD

N/A

N/A

N/A

N/A

N/A

N/A

N/A

University of Maryland

Sanford Stass/Robert Christenson

Transfer after validation of bio markers to a CLIA/CAP lab using our experience and also extensive knowledge of FDA approval and multiple successes. Also experience in core clinical lab technology with our Clinical Chemistry Research Laboratory which is CLIA/CAP and also has extensive experience in immunologic assays

100

Molecular Diagnostic Technology including sequencing and liquid biopsies.

100My

MySeq and NextSeq

N/A

All CAP Surveys

Yes

N/A

University of Michigan

Lanbo Xiao

super-high throughput qPCR (OpenArray)

500-1000

capture based RNA-seq and exosome sequencing.

100

nova-seq

N/A

N/A

N/A

N/A

University of Minnesota

Stefani Thomas

Mass spectrometry

>15,000

Automated chemistry analyzers, RT-PCR, ELISA, Next-gen sequencing, O-link, Quanterix, Flow cytometry, Long read sequencing

>600,000

Illumina Nextseq 2000, Illumina Miseq, ThermoFisher Ion GeneStudio S5 Prime with integrated Ion Chef System, Oxford Nanopore PromethION 24 (long read sequencer)

N/A

CAP, Equalis for cystatin C and iohexol, NGSP for A1C

Yes

N/A

University of Washington/Fred Hutch

Andy Hoofnagle

Immuno-MRM

>10,000

Flow cytometry, next-gen sequencing, ELISA development.

10,000

Illumina - MiSeq, NextSeq 500/550, and NextSeq 2000s.

0.4% VAF

CAP

No

Some nuances: (1) We can return results with proper consent and assay validation, (2) Some research assays do participate in EQA programs, most do not.

Massachusetts General Hospital

Steven Skates

Olink proteomics using the Target-96 platform

TBD

N/A

N/A

N/A

N/A

N/A

N/A

We collaborate with Fulgent Genetics, which assays samples in a CLIA certified US laboratory.